BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Mitchell NE, Chan SY, Jerez Diaz D, Ansari N, Lee J, Twohig P. Evolving therapeutic landscape of primary biliary cholangitis: A review. World J Hepatol 2025; 17(7): 107223 [PMID: 40747223 DOI: 10.4254/wjh.v17.i7.107223]
URL: https://www.wjgnet.com/1948-5182/full/v17/i7/107223.htm
Number Citing Articles
1
Serena Isley, Emily Johnson, Mark G. Swain, Puneeta Tandon. Fatigue in Cholestatic Liver Disease: A Review of Mechanisms and Non-Pharmacological ManagementCurrent Hepatology Reports 2025; 24(1) doi: 10.1007/s11901-025-00706-6
2
Vijay Lakshmanan, Liam Morris. Beyond Ursodeoxycholic Acid: A Comprehensive Review of Second-Line Agents in Primary Biliary CholangitisCureus 2025;  doi: 10.7759/cureus.94172
3
Min Yang, Xiaoyun Shen, Haitao Fu, Jie Lu, Fengying Li. Identification of Differentially Expressed Genes and Molecular Pathways Involved in Primary Biliary Cholangitis Using RNA-SeqGenes 2025; 17(1): 10 doi: 10.3390/genes17010010
4
Duygu Sari-Ak, Nazli Helvaci-Kurt, Fatih Con, Alev Kural. Integrative Analysis of Molecular Interactions and Repurposable Drugs in Primary Biliary CholangitisPharmedicine Journal 2026; 3(1): 45 doi: 10.62482/pmj.40
5
Fares Jamal, Amani Elshaer, Mayar H. Alatout, Nour B. Odeh, Amal Youssef, Humam Abo Abdullah, Sandra Elmasry, Tala Shahin, Hussein Abdul Nabi, Astin R. Worden, Talha A. Malik, Blanca C. Lizaola-Mayo. Second-Line Therapies in Primary Biliary Cholangitis: A Comparative Review of Obeticholic Acid, Fibrates, Seladelpar, and ElafibranorBiomedicines 2025; 13(10): 2335 doi: 10.3390/biomedicines13102335